BMSN - Bio-Matrix Scientific Group - WKN: A0NJL3 -

[JohnJohnson]

[b]BMSN - Bio-Matrix Scientific Group - WKN: A0NJL3 -
ISIN: US09065C1062 $$$$

Nach der Legalisierung den Marihuana in zwei US-Bundesstaaten, sind die sogenannten "Drug-Stocks" im Aufwind. Ein Ende ist nicht in Sicht. USA wird anscheinend wie auch Holland den Drogen-Verkauf zulassen. Mittlerweile verzeichnen die Drug-Stocks gewaltige Wertzuw

[JohnJohnson]

[b]A Very Likely $1.19 BMSN Fundamental Valuation

[JohnJohnson]

BMSN at The Ney York Times Wednesday, February 13, 2013



STRONG BULLISH $$$$$

[JohnJohnson]

BMSN on RADAR $$TARGET/ZIEL: 3,00+ US$ Dollars LONGTERM

Bio-Matrix Scientific Group (BMSN) (BMSN) announced today that its Regen BioPharma unit has appointed three internationally renowned regenerative medicine experts to its Scientific Advisory Board (SAB). The new SAB members appointed are David White, M.D., PhD; Wei-Ping Min, M.D., PhD and Vlad Bogin, M.D.

Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and PhD degrees from Cambridge University.

Dr. Wei-Ping Min is Professor at the Lawson Health Research Center in Canada. He is inventor of siRNA therapeutics in the area of immunology and cell therapy to inhibit disease modalities. He is also the founder/cofounder of several biotech companies including MedVax Pharma Corp, and ToleroTech Inc. Dr. Min brings detailed scientific and mechanistic expertise to Regen BioPharma. He earned graduate and medical degrees from Nanchang University Medical School and the PhD degree from Kyushu University.

Dr. Bogin is the President and CEO of Cromos Pharma, a contract research organization that specializes in biopharmaceutical clinical outsourcing. He was formerly the Director of Boehringer Ingelheim in charge of the phase IV program for Dabigatran Etexilate. He studied at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry.

Regen BioPharma has also entered into a Letter of Intent with Clinartis LLC, a global contract research organization (CRO). Clinartis is a full service global CRO serving pharmaceutical, biotech and medical device companies to support Phase I - IV drug and device clinical trials in the US and Europe.

The SAB and Clinartis will assist the Company in its acquisition of intellectual property related to stem cells, translation of the intellectual property into treatments, and optimizing the value of these new therapies.

"The potential of regenerative medicine products is significant," says Christopher Mizer, the President of Regen BioPharma. "We believe that strategic collaborative relationships between Regen BioPharma, our SAB and Clinartis will facilitate our efforts to create value from that potential by developing proprietary, life sciences technologies and demonstrating their clinical utility."

"Our strong SAB has scientific and regulatory expertise, coupled with Clinartis' access to world-class researchers and investigators will be very instrumental for accelerated commercialization of the cutting-edge biotechnology research on which Regen BioPharma is focused," according to Bio-Matrix Scientific Group's Chairman & CEO David Koos.

BMSN - STRONG BUY - BULLISH $$$ Target/Ziel: 3,00 US$ + Longterm

[JohnJohnson]

BMSN. BMSN. BMSN. NEWS. NEWS. Big big NEWS soon IMO. SATURDAY, FEBRUARY 16, 2013:D;)

Hear Something On The Grapevine_Bio-Matrix Scientific Group (BMSN) Shareholders Sierra Knows Something You Don't Know But Would Like Ventures Sierra World Equity Review. See Sierra's Coming Monday Headline for BMSN
HEADLINE: Hear Something On The Grapevine_Bio-Matrix Scientific Group (BMSN) Shareholders Sierra Knows Something You Don't Know But Would Like Ventures Sierra World Equity Review. See Sierra's Coming Monday Headline for BMSN. BMSN. BMSN. . BMSN. BMSN. . BMSN. BMSN. BMSN.

BMSN $ auf dem Weg in den US$ Dollar Bereich $

Bio-Matrix Scientific Group Inc. (BMSN)

0.0129+0.0015 (+13.16%)3:59P EST(OTHER OTC) - [After Hours: 0.0128-0.0001 (-0.78%) 4:00P EST]


Detailed Opinion as of Thursday, Feb 14th, 2013


Detailed Opinion
Show Signal Strength and Direction


Composite Indicators
Signal
TrendSpotter

Buy

Short Term Indicators

7 Day Average Directional Indicator

Buy

10 - 8 Day Moving Average Hilo Channel

Buy

20 Day Moving Average vs Price

Buy

20 - 50 Day MACD Oscillator

Buy


20 Day Bollinger Bands

Buy


Short Term Indicators Average: 100% Buy

20-Day Average Volume - 105,246,344

Medium Term Indicators

40 Day Commodity Channel Index

Buy

50 Day Moving Average vs Price

Buy

20 - 100 Day MACD Oscillator

Buy

50 Day Parabolic Time/Price

Buy

Medium Term Indicators Average: 100% Buy

50-Day Average Volume - 112,006,391

Long Term Indicators

60 Day Commodity Channel Index

Buy

100 Day Moving Average vs Price

Buy

50 - 100 Day MACD Oscillator

Buy

Long Term Indicators Average: 100% Buy

100-Day Average Volume - 63,871,480


Overall Average: 100% Buy

STRONG BUY $ LONG TARGET: 2,00-3,00+ US$ LONGTERM $$$$

[JohnJohnson]

$.05 once the FDA clears their initial IND.
$.05 --$.10 after they announce phase 1
$.10--$.20 after they announce phase 2
$.20--.50 after the spin the drug off to big pharma.
However, I believe that BMSN will announce a second and third IND during all of that based on their previous statements regarding their business model.
Also, there is a bit of an unknown as to how to value companies in this field so my numbers may have to be adjuated 10--50% higher depending on how the market reacts.

Quelle/Link:

[JohnJohnson]

[b]About Biotech News Stock Review. BMSN. BMSN. BMSN. News and Events
Wednesday, 06 February 2013 00:00

Regen BioPharma announced today filing of an Investigational New Drug (IND) application with the FDA to initiate clinical trials assessing the company's HemaXellerate I

[JohnJohnson]

Wensite of BMSN $$$$